Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 18/20 | 0.37 |
| ▸ | CTSK | P43235 | 6/20 | 0.37 |
| ▸ | CTSL | P07711 | 5/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8361685 | 0.89 | CTSS (0.38) | CTSSCTSKCTSLRENMEN1 | |
| SCHEMBL6076981 | 0.87 | CTSS (0.40) | CTSSCTSKCTSLMEN1ALDH1A1 | |
| SCHEMBL6076733 | 0.86 | CTSS (0.42) | CTSSCTSKMEN1ALDH1A1HTT | |
| SCHEMBL6077085 | 0.85 | CTSS (0.40) | CTSSCTSKCTSLMEN1ALDH1A1 | |
| SCHEMBL14562971 | 0.82 | CTSS (0.41) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5417343 | 0.82 | CTSS (0.41) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5435165 | 0.80 | CTSS (0.38) | CTSSCTSLMEN1ALDH1A1HTT | |
| SCHEMBL14562914 | 0.80 | CTSS (0.38) | CTSSCTSLMEN1ALDH1A1HTT | |
| SCHEMBL6467758 | 0.79 | CTSS (0.40) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL6077896 | 0.78 | CTSS (0.37) | CTSSCTSKCTSLREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | claimed |
| US-7030116-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSS 1/4885CTSK 8/4885CTSL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.